Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Prostate Cancer

Free Subscription 20.02.2023 1 BJU Int 1 Cancer 3 Cancer Res 7 Eur Urol 1 Int J Oncol 2 Int J Urol 1 Invest Radiol 1 J Clin Oncol 1 J Urol 2 N Engl J Med 3 Nat Rev Urol 1 Oncol Rep 2 Prostate 1 Urology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BJU Int

1. MA TM, Czernin J, Felix C, Alano R, et al
   LUNAR: a randomized phase 2 study of (177) Lutetium-PSMA neoadjuvant to ablative radiotherapy for oligorecurrent prostate cancer (clinical trial protocol).
   BJU Int. 2023 Feb 16. doi: 10.1111/bju.15988.
   PubMed         Abstract available
   
   

   
   Cancer

2. NYAME YA, Holt SK, Etzioni RD, Gore JL, et al
   Racial inequities in the quality of surgical care among Medicare beneficiaries with localized prostate cancer.
   Cancer. 2023 Feb 13. doi: 10.1002/cncr.34681.
   PubMed         Abstract available
   
   

   
   Cancer Res

3. BLATTI C, de la Fuente Cedeno J, Gao H, Marin-Goni I, et al
   Bayesian machine learning enables identification of transcriptional network disruptions associated with drug-resistant prostate cancer.
   Cancer Res. 2023 Feb 13:CAN-22-1910. doi: 10.1158/0008-5472.CAN-22-1910.
   PubMed         Abstract available
   
   
4. AO J, Shao X, Liu Z, Liu Q, et al
   Stimulated Raman Scattering Microscopy Enables Gleason Scoring of Prostate Core Needle Biopsy by a Convolutional Neural Network.
   Cancer Res. 2023;83:641-651.
   PubMed         Abstract available
   
   
5. ZHANG H, Jin X, Huang H
   Deregulation of SPOP in Cancer.
   Cancer Res. 2023;83:489-499.
   PubMed         Abstract available
   
   

   
   Eur Urol

6. VARATHARAJAN A, Olivier T, Prasad V
   Prostate-specific Membrane Antigen Positron Emission Tomography in the Staging of Newly Diagnosed Prostate Cancer: Is More Sensitivity Always Better?
   Eur Urol. 2023 Feb 9:S0302-2838(23)02565-4. doi: 10.1016/j.eururo.2023.
   PubMed         Abstract available
   
   
7. KIM KM, Kim JH, Chung BI
   Re: Sigrid V. Carlsson, Rebecka Arnsrud Godtman, Carl-Gustav Pihl, et al. Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality: 24-Year Follow-up of the Goteborg Randomized Populat
   Eur Urol. 2023 Feb 9:S0302-2838(23)02562-9. doi: 10.1016/j.eururo.2022.
   PubMed        
   
   
8. MONTORSI F, Scuderi S, Briganti A, Gandaglia G, et al
   Re: Melline G.M. Schilham, Mark Rijpkema, Tom Scheenen, et al. How Advanced Imaging Will Guide Therapeutic Strategies for Patients with Newly Diagnosed Prostate Cancer in the Years to Come. Eur Urol 2022;82:578-80.
   Eur Urol. 2023 Feb 9:S0302-2838(23)02563-0. doi: 10.1016/j.eururo.2022.
   PubMed        
   
   
9. OLIVIER T, Tsantoulis P, Prasad V
   Re: Darolutamide and Survival in Metastatic, Hormone-sensitive Prostate Cancer.
   Eur Urol. 2023 Feb 11:S0302-2838(23)02567-8. doi: 10.1016/j.eururo.2023.
   PubMed        
   
   
10. SCHILHAM MGM, Rijpkema M, Scheenen T, Hermsen R, et al
    Reply to Francesco Montorsi, Simone Scuderi, Alberto Briganti, and Giorgio Gandaglia's Letter to the Editor re: Melline G.M. Schilham, Mark Rijpkema, Tom Scheenen, et al. How Advanced Imaging Will Guide Therapeutic Strategies for Patients with Newly D
    Eur Urol. 2023 Feb 11:S0302-2838(23)02564-2. doi: 10.1016/j.eururo.2023.
    PubMed        
    
    
11. BERNARDINO R, Fleshner N
    Re: Sensitivity of Multiparametric MRI and Targeted Biopsy for Detection of Adverse Pathologies (Cribriform Gleason Pattern 4 and Intraductal Carcinoma): Correlation of Detected and Missed Prostate Cancer Foci with Whole Mount Histopathology.
    Eur Urol. 2023 Feb 13:S0302-2838(23)02573-3. doi: 10.1016/j.eururo.2023.
    PubMed        
    
    
12. PONTES-SILVA A
    Re: Sophie Knipper, Mehrdad Mehdi Irai, Ricarda Simon, et al. Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen-radioguided Surge
    Eur Urol. 2023 Feb 14:S0302-2838(23)02583-6. doi: 10.1016/j.eururo.2023.
    PubMed        
    
    

    
    Int J Oncol

13. MASUD N, Aldahish A, Iczkowski KA, Kale A, et al
    Zinc finger protein‑like 1 is a novel neuroendocrine biomarker for prostate cancer.
    Int J Oncol. 2023;62:38.
    PubMed         Abstract available
    
    

    
    Int J Urol

14. KRAUSEWITZ P, Farzat M, Ellinger J, Ritter M, et al
    Omitting routine cystography after RARP: Analysis of complications and readmission rates in suprapubic and transurethral drained patients.
    Int J Urol. 2023;30:211-218.
    PubMed         Abstract available
    
    
15. FURUMIDO J, Maishi N, Yanagawa-Matsuda A, Kikuchi H, et al
    Stroma biglycan expression can be a prognostic factor in prostate cancers.
    Int J Urol. 2023;30:147-154.
    PubMed         Abstract available
    
    

    
    Invest Radiol

16. BISCHOFF LM, Katemann C, Isaak A, Mesropyan N, et al
    T2 Turbo Spin Echo With Compressed Sensing and Propeller Acquisition (Sampling k-Space by Utilizing Rotating Blades) for Fast and Motion Robust Prostate MRI: Comparison With Conventional Acquisition.
    Invest Radiol. 2023;58:209-215.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

17. HUSSAIN M, Tombal B, Saad F, Fizazi K, et al
    Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.
    J Clin Oncol. 2023 Feb 16:JCO2300041. doi: 10.1200/JCO.23.00041.
    PubMed         Abstract available
    
    

    
    J Urol

18. SWAMI U, Hong A, El-Chaar NN, Ramaswamy K, et al
    The Role of Physician Specialty in the Underutilization of Standard-of-Care Treatment Intensification in Patients with Metastatic Castration-Sensitive Prostate Cancer.
    J Urol. 2023 Feb 15:101097JU0000000000003370. doi: 10.1097/JU.0000000000003370.
    PubMed         Abstract available
    
    

    
    N Engl J Med

19. FIZAZI K, Piulats JM, Reaume MN, Ostler P, et al
    Rucaparib or Physician's Choice in Metastatic Prostate Cancer.
    N Engl J Med. 2023 Feb 16. doi: 10.1056/NEJMoa2214676.
    PubMed         Abstract available
    
    
20. GAGLIANO-JUCA T, Hirsch MS, McGregor BA, Basaria S, et al
    Failure of Androgen-Deprivation Therapy Due to Ectopic hCG Secretion.
    N Engl J Med. 2023;388:660-662.
    PubMed        
    
    

    
    Nat Rev Urol

21. THOMAS T
    GHR expression and prostate cancer proliferation.
    Nat Rev Urol. 2023 Feb 13. doi: 10.1038/s41585-023-00740.
    PubMed        
    
    
22. STONE L
    PARP inhibitor response in prostate cancer.
    Nat Rev Urol. 2023 Feb 10. doi: 10.1038/s41585-023-00735.
    PubMed        
    
    
23. GERMAIN L, Lafront C, Paquette V, Neveu B, et al
    Preclinical models of prostate cancer - modelling androgen dependency and castration resistance in vitro, ex vivo and in vivo.
    Nat Rev Urol. 2023 Feb 14. doi: 10.1038/s41585-023-00726.
    PubMed         Abstract available
    
    

    
    Oncol Rep

24. XIE H, Zhao J, Wan J, Zhao J, et al
    [Corrigendum] Long non‑coding RNA AC245100.4 promotes prostate cancer tumorigenesis via the microRNA‑145‑5p/RBBP5 axis.
    Oncol Rep. 2023;49:62.
    PubMed         Abstract available
    
    

    
    Prostate

25. CHEN LC, Huang SP, Shih CT, Li CY, et al
    ATP8B1: A prognostic prostate cancer biomarker identified via genetic analysis.
    Prostate. 2023 Feb 15. doi: 10.1002/pros.24495.
    PubMed         Abstract available
    
    
26. GRAHAM LS, Haffner MC, Sayar E, Gawne A, et al
    Clinical, pathologic, and molecular features of amphicrine prostate cancer.
    Prostate. 2023 Feb 13. doi: 10.1002/pros.24497.
    PubMed         Abstract available
    
    

    
    Urology

27. HAAPIAINEN H, Valli J, Murtola T, Huhtala H, et al
    Visual Analogue Scale (VAS) in the Evaluation of Functional Outcomes After Three-dimensional Laparoscopic Prostatectomy.
    Urology. 2023;172:121-125.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: